Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | FABP3 | P05413 | 1/20 | 0.34 |
| ▸ | FABP4 | P15090 | 1/20 | 0.34 |
| ▸ | TAS1R3 | Q7RTX0 | 7/20 | 0.34 |
| ▸ | TAS1R1 | Q7RTX1 | 7/20 | 0.34 |
| ▸ | TAS1R2 | Q8TE23 | 7/20 | 0.34 |
| ▸ | MEN1 | O00255 | 5/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.34 |
| ▸ | CRHBP | P24387 | 1/20 | 0.34 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10137812 | 0.96 | SMN1; SMN2 (0.41) | FFAR1SMN1; SMN2PKMFABP3FABP4 | |
| SCHEMBL10137813 | 0.88 | SMN1; SMN2 (0.42) | FFAR1SMN1; SMN2PKMFABP3FABP4 | |
| SCHEMBL10137810 | 0.87 | FFAR1 (0.44) | FFAR1SMN1; SMN2PKMTAS1R3TAS1R1 | |
| SCHEMBL17678836 | 0.81 | TAS1R3 (0.52) | FFAR1SMN1; SMN2PKMTAS1R3TAS1R1 | |
| SCHEMBL10654634 | 0.79 | FFAR1 (0.39) | FFAR1SMN1; SMN2PKMTAS1R3TAS1R1 | |
| Methyl Alcohol SCHEMBL28841421 | 0.79 | MEN1 (0.41) | SMN1; SMN2PKMMEN1KMT2ACRHBP | |
| SCHEMBL141037 | 0.79 | CYP1A2 (0.40) | SMN1; SMN2PKMMEN1KMT2ACRHBP | |
| Acetic Acid SCHEMBL22129209 | 0.76 | FFAR3 (0.44) | SMN1; SMN2PKMMEN1KMT2ACRHBP | |
| SCHEMBL1833734 | 0.76 | SMN1; SMN2 (0.44) | SMN1; SMN2PKMFABP3FABP4TAS1R3 | |
| SCHEMBL12650279 | 0.76 | LDHA (0.40) | SMN1; SMN2PKMFABP3FABP4TAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE43298-E1 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2011-05-19 | — | — | US | disclosed |
| US-7595299-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2009-09-29 | — | — | US | disclosed |
| US-7592316-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-7244721-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. | 2007-02-08 | — | — | US | disclosed |
| US-7169760-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | FFAR1 4563/4885SMN1; SMN2 3286/4885PKM 3364/4885 |
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | HPN, TMPRSS15, VIP | FFAR1 4563/4885SMN1; SMN2 3286/4885PKM 3364/4885 |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | FFAR1 4563/4885SMN1; SMN2 3286/4885PKM 3364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.